Cronos Group Inc. is a Canada-based global cannabinoid company engaged in building intellectual property by advancing cannabis research, technology and product development. The Company operates through one segment, which is comprised of operations in Canada and Israel and is involved in the cultivation, manufacture, and marketing of cannabis and cannabis-derived products for the medical and adult-use markets. The Companyâs international brand portfolio includes Spinach, PEACE NATURALS, and Lord Jones. The Spinach brand offers pre-rolls infused with cold-filtered cannabis extract and coated in kief, and all-in-one disposable vapes. The Lord Jones is a hemp-derived cannabidiol (CBD) brand. Its Lord Jones Hash Fusions are a line-up of premium ice water hash infused pre-rolls. This brand also offers vapes and edibles. Its PEACE NATURALS offer Peppermint CBD, a blend of CBD extract, quality medium-chain triglycerides (MCT) oil, and a hint of natural peppermint flavor.

Employees

459

Sector

Pharmaceuticals

Calendar

08-06 - Q2 2025 Earnings Release (Projected)

More about the company

Quotes

Date	Price	Change	Volume
25-06-20	2.570 $	-1.15%	96,267
25-06-19	2.600 $	+0.39%	7,765
25-06-18	2.590 $	0.00%	63,206
25-06-17	2.590 $	-0.77%	71,427
25-06-16	2.610 $	-0.76%	99,440

Delayed Quote Toronto S.E., June 20, 2025 at 04:00 pm

More quotes

Income Statement and Estimates

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

2.570CAD

Average target price

3.484CAD

Spread / Average Target

+35.56%

Consensus

EPS Estimates

Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar

Market Closed - Toronto S.E. Other stock markets 16:00:00 2025-06-20 EDT			5-day change	1st Jan Change
2.570 ^CAD	-1.15%		-2.28%	-11.07%

05-08	Cronos Group Inc., Q1 2025 Earnings Call, May 08, 2025
05-08	Cronos Group Inc. announces an Equity Buyback for 19,270,951 shares, representing 5% for $50 million.	CI

Capitalization	991M 721M 626M 589M 536M 62.4B 1.12B 6.97B 2.66B 28.62B 2.71B 2.65B 105B	P/E ratio 2025 *	-301x	P/E ratio 2026 *	53.2x
Enterprise value	991M 721M 626M 589M 536M 62.4B 1.12B 6.97B 2.66B 28.62B 2.71B 2.65B 105B	EV / Sales 2025 *	4.9x	EV / Sales 2026 *	4.66x
Free-Float	52.38%	Yield 2025 *	-	Yield 2026 *	-

Cronos Group Inc., Q1 2025 Earnings Call, May 08, 2025	05-08
Cronos Group Inc. announces an Equity Buyback for 19,270,951 shares, representing 5% for $50 million.	05-08	CI
Cronos Group Up 4% in Pre-market Trade as Swings to Q1 Profit	05-08	MT
Earnings Flash (CRON.TO) Cronos Group Posts Q1 Revenue US$32.262 Million	05-08	MT
Cronos Group Brief: Q1 Net income US$7.723 Million Vs Loss $2,484 Million a Year Earlier	05-08	MT
Cronos Group Brief: Q1 Net revenue US$32.262 Million	05-08	MT
Cronos Group Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025	05-08	CI
Cronos Group Inc. authorizes a Buyback Plan.	05-06	CI
Cronos Group Inc. Unveils New Spinach 1.2g Vapes and SOURZ by Spinach Gummies Enhanced with Rare Cannabinoids	04-22	CI
Cronos Group Appoints Anna Shlimak As Chief Financial Officer; Shares Up 1% From Near 52 Week Lows In US Premarket Trade	03-19	MT
Cronos Group Appoints New CFO	03-19	MT
Cronos Group Brief: James Holm Stepping down "To Pursue other opportunities" and will remain with the Co through April 18, 2025	03-19	MT
Cronos Group Brief: Appointing Anna Shlimak as Chief Financial Officer, Effective Today; She previously served as Cronos' Chief Strategy Officer	03-19	MT

CIBC Adjusts Cronos Group Price Target to $3.50 From $3, Maintains Outperform Rating	24-05-15	MT
Bernstein Starts Cronos Group at Market Perform with CA$4.10 Price Target	22-11-02	MT
Barclays Adjusts Cronos Group's Price Target to $3.50 from $5, Maintains Equalweight Rating	22-09-30	MT
Cronos Group Price Target Raised to $7 at Raymond James	22-07-29	MT
CIBC Upgrades Cronos Group to Outperform From Neutral	22-05-12	MT

Cronos Group Inc. Stock

Equities

CRON

CA22717L1013

Pharmaceuticals

Valuation: Cronos Group Inc.

Chart: Cronos Group Inc.

Latest news: Cronos Group Inc.

Last Transcript: Cronos Group Inc.

Analysts' recommendations: Cronos Group Inc.

Press Releases: Cronos Group Inc.

News in other languages: Cronos Group Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Cronos Group Inc.

Alternative Medicine

Financials

Company Profile

Quotes

Income Statement and Estimates

Analysts' Consensus

Quarterly revenue - Rate of surprise

Cronos Group Inc. to Speak at the TD Cowen 9th Annual Future of the Consumer Conference	06-02	GL
Cronos : 2025 – Q1 Transcript	05-13	PU
Cronos: Q1 Earnings Snapshot	05-08	AQ
Cronos Group Reports 2025 First Quarter Results	05-08	GL
Cronos : 2025 Proxy	04-28	PU

Cannabis: Die Branche schwebt wieder auf Wolke sieben	23-09-02
Cannabis: El sector vuelve a dispararse	23-09-01
Cannabis : le secteur plane à nouveau	23-09-01
Bolsa de Madrid: Los osos son liberados	22-06-14
Les ours sont lâchés	22-06-14

1 day	-1.15%
1 week	-2.28%
Current month	-5.86%
1 month	-11.99%
3 months	-1.15%
6 months	-7.89%
Current year	-11.07%

1 week	2.55	2.65
1 month	2.55	2.88
Current year	2.27	3.04
1 year	2.27	3.5
3 years	2.14	4.88
5 years	2.14	20.08
10 years	0.14	32.95

Manager	Title	Age	Since
Michael Gorenstein CEO	Chief Executive Officer	38	2022-03-20
Anna Shlimak DFI	Director of Finance/CFO	39	2025-03-18
Arye Weigensberg CTO	Chief Tech/Sci/R&D Officer	42	-

Director	Title	Age	Since
Michael Gorenstein CHM	Chairman	38	2017-03-01
Jason Adler BRD	Director/Board Member	53	2016-07-11
James Rudyk BRD	Director/Board Member	58	2018-01-31

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
CRONOS GROUP INC.	-1.15%	-2.28%	-19.69%	-29.20%	721M
DONG-E-E-JIAO CO.,LTD.	+0.38%	-2.95%	-20.36%	+42.25%	4.68B
HUBEI JUMPCAN PHARMACEUTICAL CO., LTD.	-0.29%	-0.47%	-17.68%	-3.32%	3.52B
SHIJIAZHUANG YILING PHARMACEUTICAL CO., LTD.	-0.07%	-4.20%	-12.41%	-42.21%	3.24B
TASLY PHARMACEUTICAL GROUP CO., LTD	+0.45%	-3.31%	+19.14%	+49.47%	3.23B
TIANJIN PHARMACEUTICAL DA REN TANG GROUP CORPORATION LIMITED	-0.52%	-3.43%	-2.65%	+34.13%	3.1B
SHANDONG BUCHANG PHARMACEUTICALS CO., LTD.	+0.19%	-3.75%	+4.19%	-19.46%	2.35B
HENAN LINGRUI PHARMACEUTICAL CO., LTD.	-4.12%	-3.51%	-4.96%	+73.99%	1.79B
TIBET CHEEZHENG TIBETAN MEDICINE CO., LTD.	+1.91%	-6.98%	+13.20%	-14.28%	1.65B
ZHEJIANG JOLLY PHARMACEUTICAL CO.,LTD	-0.06%	-2.55%	+12.08%	+84.91%	1.62B
Average	-0.33%	-2.56%	-2.91%	+17.63%	2.59B
Weighted average by Cap.	-0.17%	-2.33%	-4.48%	+19.10%

	2025 *	2026 *
Net sales	202M 147M 128M 120M 110M 12.74B 229M 1.42B 544M 5.84B 553M 541M 21.51B	213M 155M 134M 126M 115M 13.39B 240M 1.5B 572M 6.14B 581M 568M 22.61B
Net income	-3.67M -2.67M -2.32M -2.18M -1.99M -231M -4.14M -25.8M -9.86M -106M -10.02M -9.81M -390M	30.09M 21.9M 19.02M 17.89M 16.29M 1.9B 34.01M 212M 80.94M 870M 82.22M 80.46M 3.2B
Net Debt	-	-